Abstracts Archive - Page 976 of 2607 - ACR Meeting Abstracts

Abstract Number: 030 • 2020 Pediatric Rheumatology Symposium
The Efficacy and Safety of Intraarticular Injection of Triamcinolone Acetonide versus Triamcinolone Hexacetonide in the Treatment of Juvenile Idiopathic Arthritis
Shiri Rubin ¹, Rotem Tal ², Ori Goldberg ³, Yoel Levinsky ⁴, Zohar Habot-Wilner ⁵, Orly Ohana ⁶, Yulia Gendler ⁷, Liora Harel ⁸ and Gil Amarilyo⁹, ¹Schneider Children's hospital of Israel, Tel Aviv university, Petach Tikva, Israel, ²schneider medical center, Ramat Gan, Israel, ³Schneider Children's Medical Center of Israel, Tel Aviv University, Petach Tikva, Israel, ⁴Schneider Children's Medical Cnetr of Israel, Tel Aviv University, Petach Tikva, Israel, ⁵Tel Aviv Sourasky Medical Center, Tel Aviv Univrsity, Tel Aviv, Israel, ⁶Schneider Children's Medical Cener of Israel, Petach Tikva, Israel, ⁷Schneider Children's Medical Center of Israel, Tel Aviv Univesity, Petach Tikva, Israel, ⁸Schneider Hospital, Tel Aviv University, Petah-Tiqva, Israel, ⁹Schneider Hospital, Tel Aviv University, Kibbutz Magal, Israel
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease of childhood. Intra-articular corticosteroids joint injection (IAJI) with Triamcinolone hexacetonide (TH) or triamcinolone acetonide…
Abstract Number: 031 • 2020 Pediatric Rheumatology Symposium
Exome Sequencing for Early Pediatric Systemic Lupus Erythematosus: Standard of Care in 2020?
Yike Jiang¹, Bo Yuan ¹, Marietta DeGuzman ¹, M. Cecilia Poli ², Justin Branch ¹, Andrea Ramirez ³, Martha Curry ¹, Maria Pereira ⁴, Amanda Brown ¹, W. Blaine Lapin ⁵, Sarah Nicholas ¹, Lisa Forbes ¹, Nicholas Rider ¹, Levi Watkin ¹, Jennifer Rammel ⁶, Ankur Kamdar ⁷, Melissa Mizesko ⁸, Juan Carlos Becerra ⁹, Emilina Lim ¹⁰, Eyal Muscal ¹¹, Anaid Reyes ¹, Zeynep Coban-Akdemir ¹, James Lupski ¹, Ivan Chinn ¹ and Tiphanie Vogel ¹, ¹Baylor College of Medicine, Houston, ²Universidad del Desarrollo, Santiago, Chile, ³Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, ⁴Assistant Professor, Section of Rheumatology, Division of Pediatrics, Baylor College of Medicine, Houston, Texas, ⁵, ⁶Section of Nephrology and Rheumatology, Department of Pediatrics, University of Florida Health Jacksonville, Jacksonville, Florida, ⁷Houston, ⁸Driscoll Children's Hospital, Corpus Christi, ⁹Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru, ¹⁰Children's Hospital Orange County, Orange County, ¹¹Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, houston
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease with multifactorial etiology. Identification of monogenic causes of pediatric SLE (pSLE) has yielded important insights…
Abstract Number: 032 • 2020 Pediatric Rheumatology Symposium
The Impact of Psychiatric Diagnosis and Treatment on Medication Adherence in Youth with Systemic Lupus Erythematosus
Joyce Chang¹, Alaina Davis ², Marisa Klein-Gitelman ³, Zuleyha Cidav ⁴, David Mandell ⁵ and Andrea Knight ⁶, ¹Children's Hospital of Philadelphia, Philadelphia, ²Monroe Carell Jr. Children’s Hospital at Vanderbilt, Nashville, Tennessee, ³Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, ⁴University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, ⁵Perelman School of Medicine at the University of Pennsylvania, Philadelphia, ⁶SickKids Research Institute, Toronto, Canada
Background/Purpose: Youth with systemic lupus erythematosus (SLE) experience significant health care burden and high rates of psychiatric disorders. Optimizing medication adherence is critical for preventing…
Abstract Number: 033 • 2020 Pediatric Rheumatology Symposium
Parental Adverse Childhood Experience (ACE) Exposure Is Predictive of Active Lupus in Pediatric Patients
Michael Nelson¹, Nancy Correa ², Ashley Butler ¹, Marietta De Guzman ³, Bethanie Van Horne ¹ and Christopher Greeley ¹, ¹Baylor College of Medicine, Houston, ²Texas Children's Hospital, Houston, ³Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas
Background/Purpose: Adverse Childhood Experiences (ACEs) have been recognized for more than two decades as risk factors for poor health outcomes in adults. Nevertheless, the impact…
Abstract Number: 034 • 2020 Pediatric Rheumatology Symposium
Chest Computed Tomography Manifestations in Childhood-Onset Systemic Lupus Erythematosus: A Single-Center Cohort Study
Pooja Patel¹, Gunes Orman ², Manuel Silva Carmona ³, Maria Pereira ⁴, Marietta De Guzman ⁵, Danielle Guffey ⁶, Scott Wenderfer ⁷ and R. Paul Guillerman ⁸, ¹Baylor College of Medicine, Houston, Texas, ²Edward B. Singleton Department of Radiology, Texas Children's Hospital, Houston, Texas, ³Section of Pulmonology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, ⁴Assistant Professor, Section of Rheumatology, Division of Pediatrics, Baylor College of Medicine, Houston, Texas, ⁵Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, ⁶Dan L. Duncan Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, ⁷Section of Nephrology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, ⁸Edward B. Singleton Department of Radiology, Texas Children's Hospital, Houston, Texas
Background/Purpose: Intrathoracic involvement in adults with systemic lupus erythematosus (SLE) is relatively common, particularly pleural disease. The prevalence of intrathoracic involvement in childhood-onset SLE (cSLE)…
Abstract Number: 035 • 2020 Pediatric Rheumatology Symposium
The Childhood and Rheumatology Research Alliance Systemic Lupus Erythematosus and Related Disorders Cohort
Stacy Ardoin¹, Stephen Balevic ², Aimee Hersh ³, Yukiko Kimura ⁴, Andrea Knight ⁵, Laura Schanberg ⁶, Mary Beth Son ⁷ and Timothy Beukelman ⁸ for the CARRA investigators, ¹Nationwide Children's Hospital, Columbus, ²Duke University, Hillsborough, ³University of Utah Primary Children's Hospital, Salt Lake City, ⁴Hackensack Meridian School of Medicine, Hackensack, ⁵SickKids Research Institute, Toronto, Canada, ⁶Duke Children's Hospital & Health Center, Durham, North Carolina, ⁷Boston Children's Hospital, Boston, Massachusetts, ⁸University of Alabama at Birmingham, Birmingham
Background/Purpose: Optimal therapy in childhood onset systemic lupus erythematosus (SLE) lack sufficient data to support clinical decision making. To address this knowledge gap, the Childhood…
Abstract Number: 036 • 2020 Pediatric Rheumatology Symposium
Medication Related Decision-Making in Parents of Children with Juvenile Idiopathic Arthritis
Alexandra Munroe¹, Adam Huber ², Bianca Lang ³, Suzanne Ramsey ⁴ and Elizabeth Stringer ⁴, ¹Dalhousie University, Halifax, Nova Scotia, Canada, ²IWK Health Centre & Dalhousie University, Halifax, Nova Scotia, Canada, ³Dalhousie University - Halifax, Halifax, Canada, ⁴IWK Health Centre, Halifax, Canada
Background/Purpose: Outcomes for juvenile idiopathic arthritis (JIA) have improved with use of disease-modifying anti-rheumatic drugs (DMARDs) and biologics. Despite this, the decision by a parent…
Abstract Number: 037 • 2020 Pediatric Rheumatology Symposium
Improving Pneumococcal Vaccination Rates in Immunosuppressed Rheumatology Patients
Julia Harris¹, Michael Holland ², Emily Fox ², Amy Ivy ², Maria Ibarra ², Cara Hoffart ², Jordan Jones ², Leslie Favier ³ and Ashley Cooper ², ¹Children's Mercy Kansas City, Overland Park, ²Children's Mercy Kansas City, Kansas City, ³Children's Mercy Kansas City, Leawood
Background/Purpose: The Centers for Disease Control and Prevention recommends pneumococcal vaccination of high-risk patients, including patients on iatrogenic immunosuppression. Many patients seen in the rheumatology…
Abstract Number: 038 • 2020 Pediatric Rheumatology Symposium
Change in Treatments and Outcomes After Implementation of a National Diagnosis and Treatment Guarantee Program for Juvenile Idiopathic Arthritis in Chile
Sara Concha¹, Pamela Morales ², Eduardo Talesnik ¹ and Arturo Borzutzky ¹, ¹Department of Infectious Diseases and Pediatric Immunology, School of Medicine, Pontificia Universidad Católica de Chile., Santiago, Chile, ²Department of Pediatric, Clinica Las Condes, Santiago, Chile
Background/Purpose: Juvenile idiopathic arthritis (JIA) is currently the most common childhood chronic rheumatic disease with high burden and socioeconomic costs for the patient’s family and…
Abstract Number: 039 • 2020 Pediatric Rheumatology Symposium
Assessing Patient Self-Reported Transition Readiness in a Large Pediatric Rheumatology Center
Priyanka Moolchandani ¹, Alexander Alexander ¹, Cristina Saez ¹, JaLeen Rogers ², Ariel Coleman ², Anne Dykes ², Miriah Gillispie-Taylor ³ and Tiphanie Vogel¹, ¹Baylor College of Medicine, Houston, ²Texas Children's Hospital, Houston, ³Levine Children's Hospital, Charlotte
Background/Purpose: Patients with childhood-onset rheumatologic diseases live well into adulthood and need effective transition from pediatric to adult medical providers. Fortunately, predictors of successful transition…
Abstract Number: 040 • 2020 Pediatric Rheumatology Symposium
Patient-Proxy Agreement on Mental Health and Neuropsychological Symptoms Among Youth with Juvenile Fibromyalgia Syndrome
Sabrina Gmuca¹, Maitry Sonagra ², Rui Xiao ³, Nina Thomas ⁴, Kimberly S. Miller ⁴, Jami F. Young ⁴, Pamela Weiss ⁴, David D. Sherry ⁴ and Jeffrey S. Gerber ⁴, ¹Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, ²Children's Hospital of Philadelphia, Cherry Hill, ³University of Pennsylvania, Philadelphia, ⁴Children's Hospital of Philadelphia, Philadelphia
Background/Purpose: Adolescents with juvenile fibromyalgia syndrome (JFMS) present with a myriad of mental health and neuropsychological symptoms, including dyscognition (“brain fog”); however, patient-proxy agreement on…
Abstract Number: 041 • 2020 Pediatric Rheumatology Symposium
Ancestry, Demographic and Clinical Features of Israeli Periodic Fever Aphthous Stomatitis, Pharyngitis and Adenitis (PFAPA) Syndrome – a Multi-center Cohort
Gil Amarilyo¹, Liora Harel ², Sabreen Abu Ahmad ³, Maryam Abu Rumi ³, Riva Brik ⁴, Nofar Hezkelo ⁵, Orly Ohana ⁶, Yoel Levinsky ⁷, Gabriel Chodick ⁵ and Yonatan Butbul Aviel ⁸, ¹Schneider Hospital, Tel Aviv University, Kibbutz Magal, Israel, ²Schneider Hospital, Tel Aviv University, Petah-Tiqva, Israel, ³Ruth Rappaport Children's Hospital, Rambam Medical Center, Haifa, Israel, ⁴Haifa, Israel, ⁵Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel, Tel Aviv, Israel, ⁶Schneider Children's Medical Cener of Israel, Petach Tikva, Israel, ⁷Schneider Children's Medical Cnetr of Israel, Tel Aviv University, Petach Tikva, Israel, ⁸Rambam Medical center, Haifa, Hefa, Israel
Background/Purpose: Periodic fever, aphthous stomatitis, pharyngitis and adenitis (PFAPA) syndrome is an autoinflammatory disease of unknown etiology. Recently, we showed that there may be a…
Abstract Number: 042 • 2020 Pediatric Rheumatology Symposium
Safety Analysis of Infliximab-dyyb as Compared to Infliximab in Pediatric Rheumatic Conditions
Mary Culp ¹, Dusty Lewis ¹, Bethanne Thomas ², Fatima Barbar-Smiley ³, Kyla Driest ⁴, Edward Oberle ⁴, Stacy Ardoin ¹ and Kelly Wise¹, ¹Nationwide Children's Hospital, Columbus, ²Nationwide Children's, Columbus, ³Nationwide Children's Hospital, Columbus, Ohio, ⁴Division of Rheumatology, Nationwide Children's Hospital, Columbus
Background/Purpose: Infliximab is an effective treatment for many pediatric rheumatic conditions, but high medication cost creates a barrier to patient access. Biosimilar drugs are proven…
Abstract Number: 043 • 2020 Pediatric Rheumatology Symposium
Resolution of Coronary Artery Changes in Patients with Refractory Kawasaki Disease with Prolonged Course of Infliximab: A Case Series
Shelley Shi¹ and Anusha Ramanathan ¹, ¹Kaiser Permanente Los Angeles, Los Angeles, California
Background/Purpose: Treatment for patients with Kawasaki Disease (KD) refractory to standard therapy is controversial. Most experts recommend a second dose of IVIG [1], and for…
Abstract Number: 044 • 2020 Pediatric Rheumatology Symposium
Nailing Down Nailfold Capillaroscopy Practices: A Survey of Pediatric Rheumatologists Within the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Network
Sonia Savani¹, Natasha Ruth ², Paul Nietert ¹, Gabrielle Morgan ³, Mileka Gilbert ¹ and Lauren Pachman ⁴, ¹Medical University of South Carolina, Charleston, South Carolina, ²Medical University South Carolina, Charleston, South Carolina, ³Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, Illinois, ⁴Northwestern's Feinberg School of Medicine. Ann and Robert H. Lurie Children's Hospital of Chicago; Stanley Manne Children's Research Institute of Chicago, 303 E Superior, Chicago
Background/Purpose: Juvenile dermatomyositis (JDM) is a rare systemic autoimmune disease characterized by vasculopathy and rash. The Bohan-Peter criteria for dermatomyositis are not ideal. There is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].